BDX Becton, Dickinson And

Becton, Dickinson & Co. is a medical technology company. The firm engages in the development, manufacture and sale of medical supplies, devices, laboratory equipment and diagnostic products used by healthcare institutions, physicians, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. It operates through the following segments: BD Medical, BD Life Sciences and BD Interventional. The BD Medical segment produces medical technologies and devices that are used to help improve healthcare delivery. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect infectious diseases, healthcare-associated infections and cancers. The BD Interventional segment provides vascular, urology, oncology and surgical specialty products to hospitals, individual healthcare professionals, extended care facilities, alternate site facilities, and patients via Homecare business. The company was founded in 1897 and is headquartered in Franklin Lakes, NJ.

Company profile

Thomas Polen
Fiscal year end
IRS number

BDX stock data



4 Feb 21
18 Apr 21
30 Sep 21
Quarter (USD)
Dec 20 Sep 20 Jun 20 Mar 20
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS
Annual (USD)
Sep 20 Sep 19 Sep 18 Sep 17
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Financial data from company earnings reports.

Date Owner Security Transaction Code Indirect 10b5-1 $Price #Shares $Value #Remaining
2 Mar 21 Antoine C Ezell Common Stock Payment of exercise Dispose F No No 0 505 0 4,636
1 Mar 21 Thomas J Spoerel Common Stock Grant Aquire A No No 0 302 0 1,551
1 Mar 21 Antoine C Ezell Common Stock Grant Aquire A No No 0 2,817 0 7,453
8 Feb 21 Simon D Campion Common Stock Payment of exercise Dispose F No No 0 747 0 8,434
8 Feb 21 Khichi Samrat S. Common Stock Payment of exercise Dispose F No No 0 1,616 0 4,080

Data for the last complete 13F reporting period. To see the most recent changes to ownership, click the ownership history button above.

82.3% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 1484 1397 +6.2%
Opened positions 201 123 +63.4%
Closed positions 114 114
Increased positions 565 513 +10.1%
Reduced positions 516 531 -2.8%
13F shares
Current Prev Q Change
Total value 59.83B 57.39B +4.2%
Total shares 239.02M 237.5M +0.6%
Total puts 1.08M 876.61K +23.4%
Total calls 1.01M 590.99K +71.0%
Total put/call ratio 1.1 1.5 -27.9%
Largest owners
Shares Value Change
Vanguard 24.36M $6.1B -0.9%
BLK Blackrock 22.23M $5.56B +4.0%
Wellington Management 13.45M $3.37B +16.4%
STT State Street 12.05M $3.02B -2.3%
TROW T. Rowe Price 11.64M $2.91B -35.6%
MS Morgan Stanley 7.84M $1.96B +3.4%
FMR 4.85M $1.21B -50.6%
Massachusetts Financial Services 4.43M $1.11B -2.5%
Geode Capital Management 4.16M $1.04B +2.6%
FSZ Fiera Capital 3.95M $987.61M +3.5%
Largest transactions
Shares Bought/sold Change
TROW T. Rowe Price 11.64M -6.43M -35.6%
FMR 4.85M -4.98M -50.6%
Norges Bank 2.71M +2.71M NEW
Wellington Management 13.45M +1.89M +16.4%
Veritas Asset Management 2.73M +1.17M +74.7%
Sustainable Growth Advisers 0 -1.1M EXIT
BLK Blackrock 22.23M +852.82K +4.0%
California Public Employees Retirement System 1.46M +829.63K +130.9%
1832 Asset Management 984.75K +809.36K +461.5%
Flossbach Von Storch 3.18M +572.18K +21.9%

Financial report summary

Management Discussion
  • The Medication Delivery Solutions unit's revenues in the first quarter of 2021 were primarily driven by global sales of syringes relating to COVID-19 vaccination efforts and U.S. sales of catheters and medication delivery devices that are being used to treat COVID-19 patients. First quarter revenues in the Medication Delivery Solutions unit were also favorably impacted by an acceleration of customers’ orders as they prepared for COVID-19 resurgences.
  • The Medication Management Solutions unit's revenues in the first quarter of 2021 reflected strong demand for infusion pumps which resulted from COVID-19 resurgences, particularly in Europe, and infusion pump orders placed in the United States with medical necessity certification. This demand offset the unfavorable impact to the unit’s revenues which resulted from a hold on other U.S. shipments of BD AlarisTM infusion pumps pending compliance with certain 510(k) filing requirements of the United States Food and Drug Administration (“FDA”). We continue to make progress on our regulatory filing related to the BD AlarisTM infusion pumps and we continue to expect the filing to be made with the FDA either at the end of the second quarter or early in the third quarter of BD's fiscal year 2021.
  • First quarter revenues in the Diabetes Care unit were favorably impacted by an accelerated timing of orders within fiscal year 2021, particularly in the United States. The Pharmaceutical Systems unit's revenues in the first quarter of 2021 reflected continued strength in demand for prefillable products.
Content analysis
H.S. junior Avg
New words: accelerated, acceleration, air, announced, anticorruption, appellate, Australia, bond, breach, broader, captured, center, CID, Circuit, clearance, committee, computation, country, disgorgement, EMEA, entry, expedited, fiduciary, Forlenza, formal, frequently, hearing, improper, infection, injectable, injection, injunction, insider, interrupt, Jankowski, Japan, Jeff, Korea, lawsuit, legacy, merger, modified, mutual, navigate, network, NP, outpaced, partnering, PAS, personnel, posed, presuit, proxy, purportedly, PyxisTM, quarantine, reconsider, reinvested, reinvestment, relief, remeasurement, remitted, restitution, retrospective, Ronald, rulemaking, saving, Schranz, shareholder, show, simplification, submission, surge, suspend, syringe, temporarily, transportation, treat, upgrade, upgraded, Veteran, Zealand
Removed: account, achievement, appealed, application, applied, arising, arrangement, artery, assurance, automated, automation, Bioprocessing, blood, cancer, capitalizing, cervical, combination, combine, commencement, commodity, Commonwealth, comparative, converted, culturing, cytology, destabilization, determinable, difficult, disciplined, discrete, discretionary, earliest, EMA, enacted, encourage, estate, exercise, expired, explicitly, FloChec, Franklin, guidance, heading, hosting, identification, implementation, implicit, implicitly, industrial, initially, joined, lead, lease, leasing, legislation, license, matter, maximum, microbiology, microorganism, molecular, movement, Oceania, oil, option, patient, perform, permitted, plated, practical, QuantaFloTM, rapid, rationalization, readily, real, refinancing, renew, rental, resin, respiratory, retention, satisfied, screening, sheet, significantly, specific, stronger, susceptibility, term, terminate, transition, treatment